Général Actualités Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) EN septembre 20, 2018
Général Actualités Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) EN septembre 20, 2018
Général Actualités Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria EN septembre 17, 2018
Général Actualités Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website EN septembre 10, 2018
Général Actualités ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) EN juillet 19, 2018
Général Actualités ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC EN juin 21, 2018
Général Actualités ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) EN mai 25, 2018
Général Actualités ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 EN mai 23, 2018
Général Actualités ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium EN mai 14, 2018
Général Actualités ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME EN avril 27, 2018
Général Actualités ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149 EN avril 6, 2018
Général Actualités ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME) EN avril 4, 2018
Général Actualités Réglementé Disclosure in accordance with Belgian Law of 2 May 2007 EN NL janvier 30, 2018
Général Actualités Réglementé ThromboGenics – Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy Discontinued due to Slow Recruitment Rate EN décembre 8, 2017
